Full Text
EE520 Cost-Effectiveness of Tremelimumab Plus Durvalumab for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma in the United States

Abstract

Authors

X Xiong JJ Guo

Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×